ArticleMolecular imaging and biology2026
A Claudin-1 Near-Infrared Fluorescent Antibody Conjugate for In Vivo Primary and Metastatic Colorectal Cancer Detection.
Article in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeDespite advancements in colorectal cancer (CRC) therapy, surgery remains the only curative option. Incomplete resection resulting in tumor cell positive surgical margins occurs in ~ 7% of CRC surgeries and is associated with recurrence and poor prognosis. Fluorescence-guided surgery (FGS) enhances tumor detection and enables real-time identification of tumor margins. Claudins, a large family of tight junction proteins, are being explored as cancer biomarkers and therapeutic targets due to their presence on the cell surface, tissue-specific expression, and selective upregulation in carcinomas. Claudin-1 (CLDN1) is overexpressed in CRC and associated with therapy resistance and metastasis, making it a promising target for fluorescence-based tumor detection. PROCEDURES: CLDN1 expression in CRC was analyzed using the Cancer Genome Atlas Colorectal Adenocarcinoma (TCGA-COAD) dataset. To enable in vivo tumor detection, a CLDN1 monoclonal antibody was conjugated to a near-infrared fluorescent dye (CLDN1-IR800). Sensitivity, specificity, and tumor-to-background ratio were tested in vitro and in vivo using CRC cell lines, patient-derived organoids, and an orthotopic, syngeneic model of CRC metastasis.
resultsThis study demonstrates that CLDN1 is upregulated in 100% of CRC tumors compared to patient-matched normal adjacent colon in the TCGA-COAD dataset, with an average 40-fold increase in expression. CLDN1-IR800 showed specific binding and strong fluorescence in CLDN1-expressing CRC cells, with minimal signal in non-expressing cells or IgG-IR800 controls. In vivo, CLDN1-IR800 produced a significantly higher tumor-to-background ratio in CLDN1-expressing CRC cell line and patient-derived organoid xenografts compared to CLDN1-negative tumors or IgG-IR800-injected mice. Necropsy revealed significantly higher fluorescence in tumors than in other organs. In an orthotopic syngeneic mouse model, both primary and metastatic lesions were detectable. Ex vivo imaging confirmed signal in a panel of patient-derived organoids.
conclusionsThese findings demonstrate CLDN1's potential as a target for tumor detection and FGS in CRC.
Indexed as
Identifiers
41296189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.